Asciminib bulk supplier for pharma manufacturers

Asciminib 20 mg, 40 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 20 mg, 40 mg

Reference Brands: Scemblix (USA)

Asciminib is a Oncology Cancer Care product available as Tablets in strengths 20 mg, 40 mg. It corresponds to the reference brand Scemblix (USA). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Asciminib is a targeted anticancer medication used for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It is a novel protein kinase inhibitor with a unique mechanism of action, classified as a STAMP inhibitor (Specifically Targeting the ABL Myristoyl Pocket). Unlike conventional tyrosine kinase inhibitors that bind to the ATP-binding site, asciminib selectively binds to the myristoyl pocket of the BCR-ABL1 protein, resulting in effective and sustained inhibition of leukemic cell growth.

Asciminib is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase who have previously received two or more tyrosine kinase inhibitors. It is also approved for the treatment of adults with chronic-phase Ph+ CML harboring the T315I mutation, a mutation associated with resistance to multiple standard therapies.

Marketed under the brand name Scemblix, asciminib offers a targeted treatment option for patients with limited therapeutic alternatives. Its distinct mechanism of action supports its use in resistant or refractory cases, contributing to improved disease control and long-term management of chronic myeloid leukemia.

Asciminib — third party manufacturing & bulk supply

Asciminib 20 mg, 40 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Asciminib is supplied as Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Asciminib listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Asciminib →

Back to Listing

Frequently Asked Questions

Asciminib is used for the treatment of adults with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase who have been previously treated with two or more tyrosine kinase inhibitors, including patients with the T315I mutation.

Asciminib is made from the active pharmaceutical ingredient asciminib hydrochloride, a chemically synthesized small-molecule inhibitor targeting the ABL myristoyl pocket.

The trade name of asciminib is Scemblix.

Asciminib is developed and marketed by Novartis.

The complete generic name is asciminib hydrochloride.

The brand name is Scemblix.

Asciminib is manufactured at Novartis-approved pharmaceutical manufacturing facilities in Europe and other regulated regions, depending on the market.